

Friday, 7 October 2022

RESIGNATION OF DR MICHAEL STANFORD AM

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) advises shareholders that Dr Michael Stanford AM has tendered his resignation as a non-executive director, with his resignation to take effect just prior to the conclusion of the Company's AGM on 19 October 2022.

Michael had a close association with ACL prior to its IPO, having been the group CEO of St John of God Health Care for 16 years and then a non-executive director of Clinical Labs Pty Ltd from 2016 to 2019, following its acquisition of St John of God Health Care. Since joining the Board of ACL in April 2021, Michael has acted as Chair of the Risk Committee and his medical background as a former specialist in public health medicine has made him a most valuable member of the Board. The Company would like to take this opportunity to thank Michael for his meaningful contribution to the Board over the last 18 months. The Company wishes him all the very best as he continues to pursue his non-executive career.

– ENDS –

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

Investors

Eleanor Padman

Company Secretary

Email: investors@clinicallabs.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.